ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1158

Procalcitonin Is a Biomarker for Inflammation in Outpatient Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Neupane, Sanjay P., NewYork Presbyterian, Weill Cornell Medical Center, New York, New York, United States
  • Barofsky, Alana Brooke, The Rogosin Institute, New York, New York, United States
  • Lee, John Richard, Division of Nephrology and Hypertension, Weill Cornell Medicine, New York, New York, United States
  • Silberzweig, Jeffrey I., The Rogosin Institute, New York, New York, United States
Background

Procalcitonin is a widely used test to distinguish bacterial infections from viral infections, but its level is influenced by kidney function. The normal range of procalcitonin levels in end-stage renal disease (ESRD) patients on hemodialysis (HD) is not well established. In this study, we evaluated the relationship between Procalcitonin and inflammatory markers and outcomes in ESRD outpatients on HD.

Methods

We recruited 71 ESRD outpatients on HD from October 1st 2019 to December 15th 2019 and measured their procalcitonin levels prior to dialysis. We evaluated whether procalcitonin levels were associated with clinical characteristics, laboratory parameters, and future hospitalizations and infections.

Results

In this cohort, the median procalcitonin level was 0.38 ng/mL with an interquartile range of 0.23 ng/mL and 0.54 ng/mL. The distribution of procalcitonin values are found in Fig. 1A. African Americans had a significantly higher procalcitonin level than non-African Americans (P=0.02, Wilcoxon rank sum test). ESRD outpatients who had hypertension, diabetes mellitus, or HIV did not have significantly higher procalcitonin levels than those who did not (P> 0.05). Procalcitonin levels were positively correlated with CRP (r=0.57, P<0.001) (Fig. 1B) and negatively correlated with albumin (r=-0.28, P=0.02) (Fig. 1C). Procalcitonin levels were not correlated with Kt/V, white blood cell count, and ferritin levels (P>0.05). ESRD outpatients who developed infections or who were hospitalized did not have significantly higher initial procalcitonin levels than those who did not (P>0.05).

Conclusion

Procalcitonin levels are correlated with inflammatory markers such as CRP and albumin, suggesting its potential use to identify ESRD on HD at high risk for complications, especially in the era of COVID-19.

Funding

  • Private Foundation Support